Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Raw Materials: 2022-2025

Historic Raw Materials for Rhythm Pharmaceuticals (RYTM) over the last 3 years, with Sep 2025 value amounting to $7.2 million.

  • Rhythm Pharmaceuticals' Raw Materials rose 43.01% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year increase of 43.01%. This contributed to the annual value of $6.8 million for FY2024, which is 46.51% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Raw Materials stood at $7.2 million for Q3 2025, which was up 60.35% from $4.5 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Raw Materials peaked at $7.2 million during Q3 2025, and registered a low of $2.3 million during Q2 2023.
  • Moreover, its 3-year median value for Raw Materials was $4.6 million (2023), whereas its average is $4.6 million.
  • The largest annual percentage gain for Rhythm Pharmaceuticals' Raw Materials in the last 5 years was 82.20% (2024), contrasted with its biggest fall of 31.30% (2024).
  • Rhythm Pharmaceuticals' Raw Materials (Quarterly) stood at $2.7 million in 2022, then spiked by 69.91% to $4.6 million in 2023, then spiked by 46.51% to $6.8 million in 2024, then skyrocketed by 43.01% to $7.2 million in 2025.
  • Its last three reported values are $7.2 million in Q3 2025, $4.5 million for Q2 2025, and $5.0 million during Q1 2025.